Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [Tc] (AH-113018) or CY 5** (AH-112543) Labeled Peptide
Developing an imaging agent targeting the hepatocyte growth factor receptor protein (Met) status of cancerous lesions would aid in the diagnosis and monitoring of Met-targeted tyrosine kinase inhibitors (TKIS). A peptide targeting Met labeled with [ 99m Tc] had high affinity in vitro (K d = 3.3 nM)...
Main Authors: | Elaine M. Jagoda, Sibaprasad Bhattacharyya, Joseph Kalen, Lisa Riffle, Avrum Leeder, Stephanie Histed, Mark Williams, Karen J. Wong, Biying Xu, Lawrence P. Szajek, Osama Elbuluk, Fabiola Cecchi, Kristen Raffensperger, Meghana Golla, Donald P. Bottaro, Peter Choyke |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publications
2015-09-01
|
Series: | Molecular Imaging |
Online Access: | https://doi.org/10.2310/7290.2015.00023 |
Similar Items
-
Therapeutic potential of tyrosine-protein kinase MET in osteosarcoma
by: Ming Zeng, et al.
Published: (2024-03-01) -
Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
by: Toshio Fujino, MD, et al.
Published: (2021-03-01) -
Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
by: Anna Qin, et al.
Published: (2023-10-01) -
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
by: Yu Yao, et al.
Published: (2023-01-01) -
Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
by: Lucia Demkova, et al.
Published: (2018-02-01)